Other rare ovarian cancers: Transitional cell carcinoma, malignant Brenner tumor, endometrioid carcinoma, mesothelioma, squamous cell carcinoma, sarcoma

Sahana Somasegar, Elizabeth Kertowidjojo, M. Herman Chui, Preetha Ramalingam, Ying Liu, Emeline Aviki

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter reviews the epidemiology, clinical presentation, diagnosis, pathology, treatment, surveillance guidelines, and treatment for recurrences for ultrarare ovarian malignancies based on the existing literature and by drawing from similar histologic subtypes from other primary tumor sites. Ovarian cancers are typically classified as epithelial cancers, which comprise 90% to 95% of all ovarian cancer cases, and nonepithelial cancers. Furthermore, among the nonepithelial cancers, there are a group of ultrarare subtypes, which include transitional cell carcinoma, endometrioid carcinoma, neuroendocrine tumors, mesothelioma, squamous cell carcinoma, and ovarian sarcomas. Scarce data exist on the diagnosis, treatment, management, surveillance, and recurrence treatment for these ultrarare subtypes of nonepithelial ovarian cancer, as most information comes from small case reports or case series. While there are some guidelines for management of these tumors, most of the current practice recommendations are extrapolated from guidelines for more common cancers with similar histology.

Original languageEnglish (US)
Title of host publicationDiagnosis and Treatment of Rare Gynecologic Cancers
PublisherElsevier
Pages121-141
Number of pages21
ISBN (Electronic)9780323829380
ISBN (Print)9780323829397
DOIs
StatePublished - Jan 1 2023

Keywords

  • Diagnosis
  • Endometrioid
  • Mesothelioma
  • Neuroendocrine
  • Ovarian cancer
  • Rare
  • Sarcoma
  • Squamous cell
  • Transitional cell
  • Treatment

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Other rare ovarian cancers: Transitional cell carcinoma, malignant Brenner tumor, endometrioid carcinoma, mesothelioma, squamous cell carcinoma, sarcoma'. Together they form a unique fingerprint.

Cite this